AlphAIAlphAI — Financial news for AI agents
investing.comOCT 82 min read$ANGO

AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

AngioDynamics (ANGO) reported Q1 FY2027 results beating estimates, with revenue of $80.9M and adjusted loss per share of -$0.04. Shares fell 4.26% pre-market. Med Tech segment grew 13.2%, with Auryon and NanoKnife sales increasing. Company reiterated FY2027 guidance, projecting revenue of $336M-$341M. Eric Honroth to become CEO in November 2026.

Original reporting
investing.com
Published Oct 8, 2026, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ANGO
Bearish
medium confidence
Mentioned
$ANGO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANGOBearishMed
01

Why it matters

Earnings beat but stock down, indicating market skepticism despite growth.

02

Market read

AngioDynamics' earnings release provides fresh data for med‑tech investors, with a modest beat but negative price reaction.

03

What to watch

Executive transition to new CEO Eric Honroth and continued double‑digit growth in the Med Tech segment.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

AngioDynamics is a medical technology company focused on vascular and oncology devices.

Company-level read

Ticker impact

$ANGOBearishMedium confidence
Context

AngioDynamics reported Q1 FY2027 results beating estimates (adjusted loss per share -$0.04 vs -$0.11, revenue $80.9M vs $80.5M) and the stock fell 4.26% in pre‑market trading.

Expected impact

likely continued pressure as investors digest modest beat and unchanged guidance, potential further downside.

Evidence & confidence

The beat was modest and guidance unchanged, leading to a negative market reaction despite growth in Med Tech.

Market effects

Sector

MedTech growth may support the sector, but AngioDynamics' modest beat could temper broader enthusiasm.

Regional

US med‑tech stocks may see slight pullback following the reaction.

Global

Limited impact, primarily affecting niche med‑tech investors.

Counterpoint

What could challenge this read

Despite the price drop, the earnings beat and double‑digit Med Tech growth could present a buying opportunity.

Key entities

  • company
    AngioDynamics Inc.

    Medical technology firm reporting Q1 FY2027 results.

  • executive
    Jim Clemmer

    Outgoing President and CEO of AngioDynamics.

  • executive
    Eric Honroth

    Incoming President and CEO effective November 2, 2026.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min
OCT 8
$ANGOMed

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

SEC EDGAR 8-K2 min
OCT 8
$ANGOLow

AngioDynamics, Inc. (ANGO) Appoints Eric Honroth CEO

AngioDynamics, Inc. (ANGO) named Eric Honroth as President and CEO, effective Nov. 2, 2026. He replaces Jim Clemmer, who will leave the board but stay as a consultant. The company aims to advance its transformation and Med Tech momentum under new leadership, according to the press release.

tradingview.com1 min
AUG 11
$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

yahoo.com4 min
JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min